Chemoproteomics as a basis for post-genomic drug discovery.
The large number of small organic compounds now available for drug-lead screening has led to numerous methods for classifying molecular similarity and diversity, the aim being to restore a balance between the quantity and drug-like quality of compounds in small-molecule libraries. Whereas structural and physicochemical attributes continue to be emphasized in compound selection for drug-lead screening, chemoproteomics--the use of biological information to guide chemistry--offers a highly efficient alternative to small-molecule characterization that can accelerate drug discovery in the post-genomic era.
Beroza
Paul
P
Telik, 750 Gateway Blvd, South San Francisco, CA 94080, USA. pberoza@telik.com
Villar
Hugo O
HO
Wick
Michael M
MM
Martin
Graeme R
GR
D016208:Databases, Factual; D015195:Drug Design; D004345:Drug Industry / Q000639:trends*; D004364:Pharmaceutical Preparations / Q000737:chemistry*; D020543:Proteome
D004364:Pharmaceutical Preparations; D020543:Proteome